|
Post by traderdennis on May 11, 2019 13:18:01 GMT -5
And factoring in a billion shares at that point... woohoo, market cap of $150 Billion. Pass the Kava and the hopium pipe. Probably 5 to 10 billion shares outstanding in today’s share count. I I expect to see a reverse split be put on the table in a few months combined with an increase in share count. Two pieces of bad news at once.
|
|
|
Post by mytakeonit on May 11, 2019 13:24:09 GMT -5
When you live in a tent there is no rent. Buy Mannkind until hearts content. Thanks my main mann ... and know that my heart is so overwhelmed. But, that's mytakeonit
|
|
|
Post by sportsrancho on May 11, 2019 13:57:50 GMT -5
And factoring in a billion shares at that point... woohoo, market cap of $150 Billion. Pass the Kava and the hopium pipe. Probably 5 to 10 billion shares outstanding in today’s share count. I I expect to see a reverse split be put on the table in a few months combined with an increase in share count. Two pieces of bad news at once. I can tell you if they do that I will no longer be a Mannkind believer ...they can either do what’s right for Afrezza and the shareholders, and if they have to lease it out for a royalty and manufacturing contract then so be it, and fund TS, or they can kick the can down the road to line their own pocketbooks.
|
|
|
Post by ktim on May 11, 2019 14:07:22 GMT -5
Probably 5 to 10 billion shares outstanding in today’s share count. I I expect to see a reverse split be put on the table in a few months combined with an increase in share count. Two pieces of bad news at once. I can tell you if they do that I will no longer be a Mannkind believer ...they can either do what’s right for Afrezza and the shareholders, and if they have to lease it out for a royalty and manufacturing contract then so be it, and fund TS, or they can kick the can down the road to line their own pocketbooks. So in your mind, there is likely one or more deals that are available to MNKD, it's just a matter of deciding to go down that path?
|
|
|
Post by sportsrancho on May 11, 2019 14:12:29 GMT -5
I can tell you if they do that I will no longer be a Mannkind believer ...they can either do what’s right for Afrezza and the shareholders, and if they have to lease it out for a royalty and manufacturing contract then so be it, and fund TS, or they can kick the can down the road to line their own pocketbooks. So in your mind, there is likely one or more deals that are available to MNKD, it's just a matter of deciding to go down that path? Exactly, one or more yes.
|
|
|
Post by agedhippie on May 11, 2019 16:31:07 GMT -5
I can tell you if they do that I will no longer be a Mannkind believer ...they can either do what’s right for Afrezza and the shareholders, and if they have to lease it out for a royalty and manufacturing contract then so be it, and fund TS, or they can kick the can down the road to line their own pocketbooks. So in your mind, there is likely one or more deals that are available to MNKD, it's just a matter of deciding to go down that path? I think there are always options, and the strategic review has to decide to follow them. Look at Nektar (NKTR) who produced Exubera for Pfizer. Once Pfizer withdrew from the Exubera deal their price dropped, but a decade later NKTR is still around and the price is has risen from an all time low of around $3 to the current $34 with a brief spike up to over $100 last year. These days NKTR is in oncology and pain management drugs. Interestingly they are in the process of spinning off their prospective pain medication into a separate subsidiary company part funded by capital partners. There is nothing to stop Mannkind from following the same path and putting Afrezza in to a subsidiary that is funded with new capital partners. It would likely increase the value of the company because all the sales and marketing costs associated with Afrezza would fall on the Afrezza newco. Meanwhile Mannkind would have a clearer purpose packaging drugs for inhaled delivery for companies like UTHR.
|
|
|
Post by peppy on May 14, 2019 7:49:41 GMT -5
|
|
|
Post by flipflop88 on May 14, 2019 7:50:59 GMT -5
|
|
|
Post by mnkdfann on May 14, 2019 7:52:34 GMT -5
"MannKind (NASDAQ:MNKD) initiated with Buy rating and $3 (144% upside) price target at BTIG Research citing peak sales of more than $350M for Afrezza. Analyst Robert Hazlett also likes the potential upside with technosphere programs in migraine, cystic fibrosis and cannabinoids. Shares up 10% premarket."
(From SA.)
|
|
|
Post by cretin11 on May 14, 2019 7:57:52 GMT -5
"MannKind (NASDAQ:MNKD) initiated with Buy rating and $3 (144% upside) price target at BTIG Research citing peak sales of more than $350M for Afrezza. Analyst Robert Hazlett also likes the potential upside with technosphere programs in migraine, cystic fibrosis and cannabinoids. Shares up 10% premarket." (From SA.) is BTIG legit?
|
|
|
Post by Clement on May 14, 2019 8:06:51 GMT -5
|
|
|
Post by mnkdfann on May 14, 2019 8:34:07 GMT -5
"MannKind (NASDAQ:MNKD) initiated with Buy rating and $3 (144% upside) price target at BTIG Research citing peak sales of more than $350M for Afrezza. Analyst Robert Hazlett also likes the potential upside with technosphere programs in migraine, cystic fibrosis and cannabinoids. Shares up 10% premarket." (From SA.) is BTIG legit? It's legit. Not sure how well regarded it is, but it is a solid international investment bank. www.btig.com/And it looks like the analyst isn't a total tool (unlike some analysts who have covered MNKD in the past) when you look at performance since 2009. www.tipranks.com/analysts/robert-hazlettlinkedin.com/in/robert-bert-hazlett-59455a34 Although his recent record is more hit or miss, he is still a superstar when you compare his history with MK's.
|
|
|
Post by traderdennis on May 14, 2019 10:02:07 GMT -5
"MannKind (NASDAQ:MNKD) initiated with Buy rating and $3 (144% upside) price target at BTIG Research citing peak sales of more than $350M for Afrezza. Analyst Robert Hazlett also likes the potential upside with technosphere programs in migraine, cystic fibrosis and cannabinoids. Shares up 10% premarket." (From SA.) is BTIG legit? We have seen this dance before. Firm writes a glowing report of MNKD and then in a few months there will be the same firm selling a finance and warrant package to their clients to MNKD can recapitalize.
|
|
|
Post by sportsrancho on May 14, 2019 10:04:03 GMT -5
It's legit. Not sure how well regarded it is, but it is a solid international investment bank. www.btig.com/And it looks like the analyst isn't a total tool (unlike some analysts who have covered MNKD in the past) when you look at performance since 2009. www.tipranks.com/analysts/robert-hazlettlinkedin.com/in/robert-bert-hazlett-59455a34 Although his recent record is more hit or miss, he is still a superstar when you compare his history with MK's. Wow..so good to know you compared him to MK.
|
|
|
Post by peppy on May 14, 2019 10:28:43 GMT -5
this was a replacement ATM that was expiring. The shares were already reserved for the $2.38 warrants that didn’t exercise. the price was $1.47 I believe. Cantor Fitz......
|
|